Well-known companies including Pfizer, Allergan and GlaxoSmithKline put up the price of their medicines on January 1 in a move that will lead to higher bills for patients. Now some investors are asking whether politicians might pursue regulations to curb the practice.
► Subscribe to FT.com here:
► Subscribe to the Financial Times on YouTube:
For more video content from the Financial Times, visit http://www.FT.com/video
Twitter https://twitter.com/ftvideo
Facebook https://www.facebook.com/financialtimes
